跳至主要内容
临床试验/NL-OMON47080
NL-OMON47080已完成不适用

ong Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients with Crohn*s Disease - SPM-010

SetPoint Medical Corporation0 个研究点目标入组 3 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients must have enrolled in study SPM-007; including patients who either completed that study or withdrew before completion of that study.

排除标准

  • Patients who meet any of the following criteria are not to be enrolled in
  • this study:
  • * Inability to provide informed consent
  • * Significant psychiatric illness or substance abuse
  • * All patients will be excluded who have developed any of these exclusionary conditions during the SMP-007 study, or in the interim between SPM-007 and the Day 0 of SPM-010:
  • o History of unilateral or bilateral vagotomy
  • o History of recurrent vaso-vagal syncope episodes
  • o Known obstructive sleep apnea
  • o Known history of cardiac rhythm disturbances, atrioventricular block of greater than first degree, or cardiac conduction pathway abnormalities other than isolated right bundle branch block or isolated left anterior fascicle block.
  • o Significant pharyngeal dysfunction or swallowing difficulties
  • o Clinically significant vocal cord damage or hoarseness
  • o Other implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverterdefibrillators)
  • o Asthma or chronic obstructive pulmonary disease not controlled by medications, or any other disease causing clinically significant dyspnea
  • o A greater than or equal to 40 pack-year smoking history
  • o Active peptic ulcer disease
  • o Patients with a limited life expectancy due to terminal illness.
  • * If the patient has previously discontinued SPM-007 and greater than 30 days have elapsed since the final visit in SPM-007, the interim history including medical history, adverse events, device deficiencies, and concomitant medications will be assessed to determine if these preclude safe enrollment.

研究者

相似试验